Cash and cash equivalents (USD, thousands)

Accounts receivable, net (USD, thousands)

Inventory (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Property and equipment, net (USD, thousands)

Goodwill (USD, thousands)

Intangible assets, net (USD, thousands)

Other assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued expenses and other current liabilities (USD, thousands)

Deferred revenue (USD, thousands)

Current portion of payable to related parties pursuant to the Tax Receivable Agreement (USD, thousands)

Current portion of long-term debt (USD, thousands)

Current portion of finance lease liabilities (USD, thousands)

Total current liabilities (USD, thousands)

Long-term debt, less current portion (USD, thousands)

Finance lease liabilities, less current portion (USD, thousands)

Other long-term liabilities (USD, thousands)

Total liabilities (USD, thousands)

Class A common stock, $ 0.01 par value (USD, thousands)

Class B common stock, $ 0.01 par value (USD, thousands)

Additional paid-in capital (USD, thousands)

Retained earnings (USD, thousands)

Total stockholders’ equity attributable to Maravai LifeSciences Holdings, Inc. (USD, thousands)

Non-controlling interest (USD, thousands)

Total stockholders’ equity (USD, thousands)

Total liabilities and stockholders’ equity (USD, thousands)

99bb62ee06f7ca7db8fca0fcddca45faaf921ac9ac36279369f87313c0f66af5

Revenue (USD, thousands)

Cost of Revenue (USD, thousands)

Selling, General and Administrative Expenses (USD, thousands)

Research and Development Expenses (USD, thousands)

Change in Estimated Fair Value of Contingent Consideration (USD, thousands)

Goodwill Impairment (USD, thousands)

Restructuring Expenses (USD, thousands)

Total Operating Expenses (USD, thousands)

(Loss) Income from Operations (USD, thousands)

Interest Expense (USD, thousands)

Interest Income (USD, thousands)

Loss on Extinguishment of Debt (USD, thousands)

Change in Payable to Related Parties Pursuant to the Tax Receivable Agreement (USD, thousands)

Other Expense (USD, thousands)

(Loss) Income Before Income Taxes (USD, thousands)

Income Tax (Benefit) Expense (USD, thousands)

Net (Loss) Income (USD, thousands)

Net (Loss) Income Attributable to Non-Controlling Interests (USD, thousands)

Net (Loss) Income Attributable to Maravai LifeSciences Holdings, Inc. (USD, thousands)

94f2322b0a4fc74a0e404c9a9537205950bbef4fad913ee52a5e250573f7d0be

North America

EMEA

Asia Pacific

Latin America

Total Revenue

8fdae684060410c36b21490c409807756d21fb69ff882ed9f5fa3d13cbc92207

52f66866ea9aedc3de92b93e36afb7a3bddac3a19c551e08c5b0f75670090c4d

Nucleic Acid Production

- CleanCap Revenue

- CleanCap Revenue from COVID-19-related products

Biologics Safety Testing

94171a7f882086fe313e3d5737afe3bc543cd4afdb34e01b0ef9b90b2099a45f

MARAVAI LIFESCIENCES HOLDINGS (MRVI)

Financials